Sienna Biopharmaceuticals’ struggles doomed company
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Cure Pharmaceutical looks to acquire Coeptis Pharmaceuticals
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Tri-county biotech upstarts struggle to maintain stock prices
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Our view: Setbacks are costly but biotech industry copes
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Atara hiring 100 workers in Conejo Valley
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen lawsuit over cholesterol drug will get new trial
An Amgen lawsuit against a competing cholesterol drug will get a new trial but sales of the drug will be allowed in the U.S. until a decision is rendered. A federal court of appeals judge threw out a ban on the sale of Praluent, manufactured by New York-based Regeneron Pharmaceuticals and French biotech company Sanofi Read More →
Read More →Amgen spends big to defeat Proposition 61
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →
